ID Biomedical announces positive results from human testing of intranasal flu vaccine

- Subunit flu vaccine safe, well tolerated and elicits both mucosal

and systemic immune responses.



- John Treanor, M.D., Principal Investigator, presents flu data at the

Fourth Annual Conference on Vaccine Research in Arlington, Virginia

on April 24, 2001, a meeting sponsored by the National Foundation of

Infectious Diseases in collaboration with the CDC, NIAID, USDA, CBER

FDA and the WHO.



Trading Symbols - NASDAQ - "IDBE", TSE - "IDB"



Apr 24, 2001, 01:00 ET from ID Biomedical Corporation

    VANCOUVER, April 24 /PRNewswire/ - ID Biomedical Corporation today
 announced positive results from the human testing of a subunit, intranasal,
 prototype influenza (flu) vaccine under development by Intellivax
 International Inc. ID Biomedical is in the process of closing its acquisition
 of Intellivax.
     The results showed that, at three different doses, the vaccine was safe
 and well tolerated. Additionally, human subjects developed both mucosal and
 systemic immune responses.
     "I'm very excited about the results from this clinical trial," stated Dr.
 John Treanor, Associate Professor of Medicine, University of Rochester and
 Principal Investigator for the study. "We showed that the proteosome-flu
 vaccine given as a nasal spray induced high levels of secretory IgA antibodies
 in nasal secretions. In addition, this intranasal vaccine also generated
 significant levels of hemagglutination-inhibiting antibodies in the
 bloodstream. It is remarkable and quite encouraging that this non-living,
 subunit intranasal flu vaccine can elicit significant levels of potentially
 protective antibodies in both nasal secretions and in the blood stream."
     The potential competitive advantages offered by the ID
 Biomedical/Intellivax flu vaccine include ease of administration (no needles),
 safety (the vaccine is non-living, based on purified proteins), broad immunity
 (mucosal and systemic antibodies), a simple manufacturing strategy (compatible
 with flu antigen produced in either eggs or in cell culture) and stability
 (the vaccine exhibits an improved storage temperature profile).
     The ID Biomedical/Intellivax flu vaccine is based on Intellivax's
 proprietary vaccine delivery/adjuvant technology, Proteosomes. This proteosome-
 flu vaccine is created by combining proteosomes with a preparation of
 influenza proteins that include the hemagglutinin. Immune responses against
 the hemagglutinin are known to be associated with protection against influenza
 infection and include the hemagglutination-inhibiting antibodies found in the
 bloodstream after immunization with the nasal proteosome-flu vaccine. In
 adults, such serum antibodies are typically elicited most strongly by an
 injectable vaccine.
     "The levels of secretory IgA antibodies induced by our proteosome-flu
 vaccine were similar to levels of IgA elicited by the live cold-adapted virus
 vaccine which has shown protection in humans," said George Lowell, M.D.,
 President and Chief Scientific Officer of Intellivax. "This flu vaccine data
 emphasizes the value of our proprietary proteosome technology which we believe
 has broad utility for delivering nasal spray vaccines to protect against many
 diseases."
     Influenza (flu) is caused by the influenza virus, which infects the
 respiratory tract. The World Health Organization estimates that in North
 America and Europe this highly contagious disease affects 70 - 150 million
 people annually and causes up to 125,000 deaths. Additionally, influenza is a
 major cause of absenteeism from work and school.
     The direct costs associated with the diagnosis and treatment of influenza
 and the indirect costs associated with days of work lost due to illness are a
 tremendous burden to society. Health authorities recommended annual
 vaccination as the best and most cost effective protection against influenza.
 In the United States, the Advisory Committee on Immunization Practice (ACIP)
 recently lowered the age for universal vaccination from 65 years of age to 50
 years of age (76 million people). The ACIP is currently considering
 recommending routine vaccination of young healthy children not only to prevent
 illness, but also because of their role in spreading the virus. Employers are
 also encouraging flu vaccinations by offering them in the workplace.
     The flu vaccine market is expected to experience rapid growth in the
 coming decade as health authorities recommend universal vaccination to a
 larger and larger proportion of the population. Additionally, the introduction
 of more user-friendly intranasal flu vaccines is expected to further expand
 the market.
     "The current flu vaccines on the market are all injectable killed
 vaccines. The next generation of flu vaccines will be intranasal products.
 Aviron's FluMist(TM) which is a live cold-adapted virus vaccine, sprayed into
 the nose, should hit the market in the next two years," said Anthony Holler,
 M.D., CEO of ID Biomedical. "This flu vaccine has the advantage of being a non-
 living product which is delivered by nasal spray. The results of this first
 clinical trial show that, from an immunity standpoint, this product may
 combine some of the best features of live intranasal vaccines and the current
 injectable vaccines."
 
     About ID Biomedical
     ID Biomedical Corporation is a North American-based biotechnology company
 focused on the development of proprietary vaccine and immunotherapeutic
 products, and is also focused on the development of a proprietary gene
 identification system, Cycling Probe(TM) Technology, for applications in
 genomics and diagnostics.
     ID Biomedical is developing vaccines for the prevention of a number of
 different diseases. The Company's lead product in clinical development is
 StreptAvax(TM), a vaccine for the prevention of diseases caused by group A
 streptococcus. Additionally the Company has a number of vaccines in
 preclinical development.
     ID Biomedical has recently signed an agreement to acquire Intellivax
 International, Inc. of Ville St-Laurent, Quebec. Intellivax's lead product in
 clinical development is a new intranasal influenza vaccine formulated with its
 proprietary mucosal delivery technology called proteosomes. Intellivax is
 focused on developing vaccines delivered by nasal spray using the proteosomes
 technology.
     ID Biomedical is licensing Cycling Probe(TM) Technology as well as its
 broad patents in signal amplification to the genomics and diagnostic industry
 for further product and technology development. Currently, Applied Biosystems
 (NYSE:   ABI - news), Mitsubishi Chemical Corporation, Alexon-Trend, a
 subsidiary of Apogent Technologies, formerly Sybron International (NYSE:   AOT -
 news), DiscoveRx, and Third Wave Technologies have obtained rights to ID
 Biomedical's patents.
 
     The foregoing information contains so-called forward-looking statements.
 These include statements about ID Biomedical's expectations, beliefs,
 intentions or strategies for the future, which it indicates by words or
 phrases such as "anticipate", "expect", "intend", "plan", "will", "we
 believe", "ID Biomedical believes", "management believes" and similar
 language. All forward-looking statements are based on ID Biomedical's current
 expectations and are subject to risks uncertainties and to assumptions made.
 Important factors that could cause actual results to differ materially from
 those expressed or implied by such forward-looking statements include: (i) the
 ability to successfully complete preclinical and clinical development of its
 products; ii) the ability to obtain and enforce timely patent and intellectual
 property protection for its technology and products; iii) the ability to
 avoid, either by product design, licensing arrangement or otherwise,
 infringement of third parties' intellectual property; iv) decisions, and the
 timing of decisions, made by the health regulatory agencies regarding approval
 of its products for human testing; v) the ability to complete and maintain
 corporate alliances relating to the development and commercialization of its
 technology and products, vi) market acceptance of its technology and products,
 and (vii) the competitive environment and impact of technological change. ID
 Biomedical bases its forward-looking statements on information currently
 available to it, and assumes no obligation to update them.
 
 

SOURCE ID Biomedical Corporation
    VANCOUVER, April 24 /PRNewswire/ - ID Biomedical Corporation today
 announced positive results from the human testing of a subunit, intranasal,
 prototype influenza (flu) vaccine under development by Intellivax
 International Inc. ID Biomedical is in the process of closing its acquisition
 of Intellivax.
     The results showed that, at three different doses, the vaccine was safe
 and well tolerated. Additionally, human subjects developed both mucosal and
 systemic immune responses.
     "I'm very excited about the results from this clinical trial," stated Dr.
 John Treanor, Associate Professor of Medicine, University of Rochester and
 Principal Investigator for the study. "We showed that the proteosome-flu
 vaccine given as a nasal spray induced high levels of secretory IgA antibodies
 in nasal secretions. In addition, this intranasal vaccine also generated
 significant levels of hemagglutination-inhibiting antibodies in the
 bloodstream. It is remarkable and quite encouraging that this non-living,
 subunit intranasal flu vaccine can elicit significant levels of potentially
 protective antibodies in both nasal secretions and in the blood stream."
     The potential competitive advantages offered by the ID
 Biomedical/Intellivax flu vaccine include ease of administration (no needles),
 safety (the vaccine is non-living, based on purified proteins), broad immunity
 (mucosal and systemic antibodies), a simple manufacturing strategy (compatible
 with flu antigen produced in either eggs or in cell culture) and stability
 (the vaccine exhibits an improved storage temperature profile).
     The ID Biomedical/Intellivax flu vaccine is based on Intellivax's
 proprietary vaccine delivery/adjuvant technology, Proteosomes. This proteosome-
 flu vaccine is created by combining proteosomes with a preparation of
 influenza proteins that include the hemagglutinin. Immune responses against
 the hemagglutinin are known to be associated with protection against influenza
 infection and include the hemagglutination-inhibiting antibodies found in the
 bloodstream after immunization with the nasal proteosome-flu vaccine. In
 adults, such serum antibodies are typically elicited most strongly by an
 injectable vaccine.
     "The levels of secretory IgA antibodies induced by our proteosome-flu
 vaccine were similar to levels of IgA elicited by the live cold-adapted virus
 vaccine which has shown protection in humans," said George Lowell, M.D.,
 President and Chief Scientific Officer of Intellivax. "This flu vaccine data
 emphasizes the value of our proprietary proteosome technology which we believe
 has broad utility for delivering nasal spray vaccines to protect against many
 diseases."
     Influenza (flu) is caused by the influenza virus, which infects the
 respiratory tract. The World Health Organization estimates that in North
 America and Europe this highly contagious disease affects 70 - 150 million
 people annually and causes up to 125,000 deaths. Additionally, influenza is a
 major cause of absenteeism from work and school.
     The direct costs associated with the diagnosis and treatment of influenza
 and the indirect costs associated with days of work lost due to illness are a
 tremendous burden to society. Health authorities recommended annual
 vaccination as the best and most cost effective protection against influenza.
 In the United States, the Advisory Committee on Immunization Practice (ACIP)
 recently lowered the age for universal vaccination from 65 years of age to 50
 years of age (76 million people). The ACIP is currently considering
 recommending routine vaccination of young healthy children not only to prevent
 illness, but also because of their role in spreading the virus. Employers are
 also encouraging flu vaccinations by offering them in the workplace.
     The flu vaccine market is expected to experience rapid growth in the
 coming decade as health authorities recommend universal vaccination to a
 larger and larger proportion of the population. Additionally, the introduction
 of more user-friendly intranasal flu vaccines is expected to further expand
 the market.
     "The current flu vaccines on the market are all injectable killed
 vaccines. The next generation of flu vaccines will be intranasal products.
 Aviron's FluMist(TM) which is a live cold-adapted virus vaccine, sprayed into
 the nose, should hit the market in the next two years," said Anthony Holler,
 M.D., CEO of ID Biomedical. "This flu vaccine has the advantage of being a non-
 living product which is delivered by nasal spray. The results of this first
 clinical trial show that, from an immunity standpoint, this product may
 combine some of the best features of live intranasal vaccines and the current
 injectable vaccines."
 
     About ID Biomedical
     ID Biomedical Corporation is a North American-based biotechnology company
 focused on the development of proprietary vaccine and immunotherapeutic
 products, and is also focused on the development of a proprietary gene
 identification system, Cycling Probe(TM) Technology, for applications in
 genomics and diagnostics.
     ID Biomedical is developing vaccines for the prevention of a number of
 different diseases. The Company's lead product in clinical development is
 StreptAvax(TM), a vaccine for the prevention of diseases caused by group A
 streptococcus. Additionally the Company has a number of vaccines in
 preclinical development.
     ID Biomedical has recently signed an agreement to acquire Intellivax
 International, Inc. of Ville St-Laurent, Quebec. Intellivax's lead product in
 clinical development is a new intranasal influenza vaccine formulated with its
 proprietary mucosal delivery technology called proteosomes. Intellivax is
 focused on developing vaccines delivered by nasal spray using the proteosomes
 technology.
     ID Biomedical is licensing Cycling Probe(TM) Technology as well as its
 broad patents in signal amplification to the genomics and diagnostic industry
 for further product and technology development. Currently, Applied Biosystems
 (NYSE:   ABI - news), Mitsubishi Chemical Corporation, Alexon-Trend, a
 subsidiary of Apogent Technologies, formerly Sybron International (NYSE:   AOT -
 news), DiscoveRx, and Third Wave Technologies have obtained rights to ID
 Biomedical's patents.
 
     The foregoing information contains so-called forward-looking statements.
 These include statements about ID Biomedical's expectations, beliefs,
 intentions or strategies for the future, which it indicates by words or
 phrases such as "anticipate", "expect", "intend", "plan", "will", "we
 believe", "ID Biomedical believes", "management believes" and similar
 language. All forward-looking statements are based on ID Biomedical's current
 expectations and are subject to risks uncertainties and to assumptions made.
 Important factors that could cause actual results to differ materially from
 those expressed or implied by such forward-looking statements include: (i) the
 ability to successfully complete preclinical and clinical development of its
 products; ii) the ability to obtain and enforce timely patent and intellectual
 property protection for its technology and products; iii) the ability to
 avoid, either by product design, licensing arrangement or otherwise,
 infringement of third parties' intellectual property; iv) decisions, and the
 timing of decisions, made by the health regulatory agencies regarding approval
 of its products for human testing; v) the ability to complete and maintain
 corporate alliances relating to the development and commercialization of its
 technology and products, vi) market acceptance of its technology and products,
 and (vii) the competitive environment and impact of technological change. ID
 Biomedical bases its forward-looking statements on information currently
 available to it, and assumes no obligation to update them.
 
 SOURCE ID Biomedical Corporation